Feb 5, 2026 09:15AM
Feb 4, 2026 08:47AM
Feb 4, 2026 08:45AM
Jan 28, 2026 08:45AM
Jan 28, 2026 08:45AM
Jan 26, 2026 08:30AM
Jan 21, 2026 04:01PM GRI Bio completes 1-for-28 reverse stock split to meet NASDAQ requirements
Jan 21, 2026 04:01PM
Jan 8, 2026 08:00AM
Jan 8, 2026 08:00AM
Dec 12, 2025 04:05PM
Dec 12, 2025 04:05PM
Dec 11, 2025 09:15AM
Dec 11, 2025 09:15AM GRI Bio Announces Pricing of $8,000,000 Million Public Offering
Dec 10, 2025 04:05PM
Dec 10, 2025 04:05PM
Sep 11, 2025 08:45AM
Sep 11, 2025 08:45AM
Jul 31, 2025 09:00AM
Jul 31, 2025 09:00AM
Jul 1, 2025 08:45AM GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)
Jun 26, 2025 08:08AM
Jun 26, 2025 08:00AM
May 22, 2025 08:03AM
May 22, 2025 08:00AM
May 15, 2025 08:35AM
May 15, 2025 08:35AM
May 8, 2025 08:48AM GRI Bio, Inc (GRI) Reports Interim Biomarker Data Showing Positive Trend Towards Anti-Fibrotic Effect with GRI-0621
May 8, 2025 08:45AM
May 7, 2025 09:15AM
Apr 16, 2025 08:35AM
Apr 2, 2025 04:05PM
Apr 1, 2025 11:15AM
Apr 1, 2025 11:15AM
Apr 1, 2025 09:00AM GRI Bio, Inc (GRI) Reports Encouraging Interim 2-Week Safety Results from Ongoing Phase 2a Study of GRI-0621
Apr 1, 2025 09:00AM
Mar 31, 2025 08:03AM
Mar 31, 2025 08:00AM
Mar 18, 2025 09:05AM
Mar 17, 2025 08:05AM
Mar 11, 2025 08:35AM
Mar 11, 2025 08:35AM GRI Bio Regains Compliance with Nasdaq’s Minimum Bid Price Rule
Feb 19, 2025 04:05PM
Feb 19, 2025 04:05PM
Feb 19, 2025 09:00AM
Dec 23, 2024 09:00AM
Nov 21, 2024 08:45AM
Nov 21, 2024 08:45AM
Nov 14, 2024 04:20PM GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis
Oct 24, 2024 08:34AM

1,122,779 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All